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Abstract
Colorectal small cell carcinoma (SmCC) is a rare tumor with an aggressive course. The aim of this
study is to summarize our experience with this tumor and to highlight its immunohistochemical
profile. Ten cases of colorectal SmCC were identified in our files and a panel of immunostains was
performed. Follow up was available for the average of 3 years, during which 7 patients died and 3
were alive with disease. All cases were positive for LMWK, CK 19 and pancytokeratin but were
negative for TTF-1 and CA 125. EGFR was positive in 7 cases. TTF-1 negative staining may be
valuable in differentiating it from its pulmonary counterpart. CDX2, mCEA, CD56, synaptophysin,
NSE and chromogranin can help differentiate it from non-endocrine poorly differentiated
adenocarcinoma. The expression of EGFR in a subset of patients has not been reported earlier and
has to be evaluated in larger series to assess its role in the planning of targeted biologic therapy.
Background
Primary extra-pulmonary small cell carcinoma (SmCC) is
a rare tumor encountered in several organ systems. In the
digestive system, neuroendocrine carcinomas comprise
less than 1% of all colorectal cancer and are classically
associated with poor outcome [1]. In the few reports of
colorectal SmCC (CRSmCC) in the English literature,
these tumors show a similar demographic characteristics
to colorectal adenocarcinomas with the exception of
being more common in females. Because of the difference
in prognosis and management between the two tumor
types, the distinguishing histological and immunopheno-
typic features need to be well characterized. The aim of
this study is to describe a single institution's experience
with this rare tumor, focusing on its immunohistochemi-
cal features and possible utilization.
Materials and methods
This study was approved by the Institutional Research Eth-
ics Board. Since a relatively new laboratory information
system was installed in 1999, we were able to search the
Anatomic Pathology database and the electronic patients'
charts, between 1999 and 2006 for CRSmCC in Sunny-
brook Health Sciences Center. Demographic information,
clinical data, tumor stage, treatment and follow up were
reviewed. Patients with colorectal well-differentiated neu-
roendocrine tumors (carcinoid tumor), large cell neu-
roendocrine carcinoma, poorly differentiated carcinoma
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with focal neuroendocrine differentiation or with history
of Merkel cell tumors of the skin, primary SmCC of the
lung or other organs were excluded. All patients included
in this study had either chest plain radiograph or a chest
CT that was free of tumor.
H&E-stained sections were reviewed by two pathologists
to confirm the diagnosis. The histological criteria applied
for the diagnosis were the same as those used for the diag-
nosis of pulmonary SmCC. These criteria required that the
entire tumor in the submitted material consists of cohe-
sive round to oval cells with sparse cytoplasm, nuclei with
salt and pepper chromatin, nuclear moulding and small
or inconspicuous nucleoli. These features needed to be
present in the setting of brisk mitoses, apoptosis and
necrosis (Figure 1). As per the local surgical pathology
protocols, submitted representative tissue sections were
routinely processed and embedded in paraffin. Sections
(2–3 µm) of the tumor, through its most invasive part and
including adjacent normal mucosa when possible, were
stained for immunohistochemistry using standard avidin-
biotin complex method. The panel of antibodies used
summarized in Table 1. Results of immunostains were
assessed by two pathologists and a consensus regarding
controversial cases was reached at the double-headed
microscope. Evaluation of the immunohistochemical
staining was performed by light microscopy using a 10×
eye-piece lense with the selective use of 20 – 40× objective
lense for confirmation. The markers were evaluated by a
semiquantitative method. With the exception of CDX2
and TTF-1 which showed nuclear staining, and EGFR
which showed cell membrane staining, cytoplasmic stain-
ing was required for all other immunostains.
Results
Ten patients with primary CRSmCC were identified with
their demographic and clinical findings summarized in
Table 2. Their age ranged from 39 – 88 (median = 60).
There were 7 females and 3 males. Family history of color-
ectal cancer was present in one patient and 2 had a history
of inflammatory bowel disease. Three patients had syn-
chronous adenomas in the large bowel. Nine cases pre-
sented with symptoms related to a colorectal mass and/or
metastasis while one case presented with biliary colic.
Seven cases had tumors arising in the rectum including
the anorectal junction. Nine of the ten patients had dis-
tant metastases at the time of diagnosis. The commonest
metastatic site was the liver present in 6 cases.
On routine H&E sections, all our cases showed solid nests
and clusters of small to medium sized cells, displaying
prominent apoptosis, nuclear moulding, brisk mitosis
(>10/10 HPFs) and necrotic foci. Their nuclei showed
classic salt and pepper chromatin with indistinct nucleoli.
Occasional rosette formation was noted. Two of the cases
were associated with other colonic pathology; one of
which showed a colonic adenoma away from the SmCC
while the other showed colonic adenocarcinoma arising
from tubulovillous adenomas, merging with the lateral
edge of the SmCC. In all the cases, there was no evidence
of divergent differentiation in tehe form of squamous, aci-
nar (glandular) or large cell neuroendocrine. Lymphovas-
cular invasion was present in all of our cases. None of the
cases showed Azzopardi effect, however crushing artefacts
were noted in all the cases.
Our immunohistochemical panel showed that all cases
were positive for low molecular weight cytokeratin
(LMWK), CK 19 and pancytokeratin but were negative for
TTF-1 and CA 125. CK 7 expression was variable but that
of CK 20 was restricted to tumors of the right colon.
Immunostaining for neuroendocrine differentiation
including CD56, synaptophysin, NSE, and chromogranin
was variable but every case showed positivity with at least
one of these markers (Figures 2 and 3). CDX2 was positive
in only 2 cases while mCEA was positive in 2 cases. EGFR
was positive in 7 cases (Figure 4). Results of the immuno-
histochemistry are summarized in Table 3. The case with
the associating adenocarcinoma component showed sim-
ilar immunohistochemical profile (including EGFR
expression) in both tumors, except for the lack of CD56,
synaptophysin and chromogranin expressions and the
presence of CEA expression in the adenocarcinoma.
A colonic small cell carcinoma with brisk mitoses, apoptosis  and necrosis Figure 1
A colonic small cell carcinoma with brisk mitoses, apoptosis 
and necrosis. Adjacent colonic mucosal crypts are non-dys-
plastic. (H&E × 400).Diagnostic Pathology 2007, 2:35 http://www.diagnosticpathology.org/content/2/1/35
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The standard management for CRSmCC during this
period of review was combined chemotherapy and radio-
therapy similar to protocols used in SmCC of the lung.
Five patients received VP16 and cis-platinum with or
without consolidation therapy to the local disease. How-
ever, two patients deteriorated rapidly and died of meta-
static disease prior to the initiation of systemic
chemotherapy. Four cases were treated by surgery (2 with
right hemicolectomy, 1 with low anterior resection and 1
with abdomino-perineal resection) with or without post-
operative adjuvant chemotherapy.
The median follow up was 3 years (10 months – 4 years),
during which 7 patients died of disease. The remaining 3
cases were alive with disease at last follow-up.
Discussion
Primary extra-pulmonary SmCC is uncommon, occurring
in only 4% of all patients with SmCC [2]. While its actual
incidence may be underestimated, SmCC presents 0.1%
to 1% of all gastrointestinal (GI) malignancies, with vary-
ing incidence in different organs [3]. SmCC is estimated to
represent 1% to 2.8% of all esophageal cancer, with the
esophagus being the commonest site for GI SmCC [4-9].
The second most common location is the colorectum
where SmCC accounts for 0.2%–0.8% of all colorectal
neoplasms [10-12]. Primary SmCC has been described in
most organs of the body [3,13-20], except the central
nervous system.12 The majority of patients with GI SmCC
present with overt distant metastases [3]. In our study, the
commonest symptom was abdominal pain and 9 of our
10 cases had metastatic disease at the time of diagnosis.
The commonest primary site is the rectum, followed by
the cecum and sigmoid colon [3]. Similarly, in our series,
the tumor occurred in the rectum including the anorectal
junction in 7 patients. In one series, a predominance of
the disease in older men (mean age = 64 years) was
reported [3]. Our patients ranged in age from 39–88 years
old with a median age of 60 years and showed a female
predominance with a female to male ratio of 2:1. Three of
our 10 cases had adenomas in the vicinity of their tumors
and 2 had inflammatory bowel disease but none was
immunodeficient. The association of CRSmCC with
inflammatory bowel disease and adenoma either within
or away from the SmCC has been documented earlier
[10,21], however their possible role in CRSmCC carcino-
genesis remains uncertain.
The role of immunohistochemistry in establishing the
diagnosis of CRSmCC has been a subject of considerable
debate. To some authors, the classic histological features
on H&E-stained sections are sufficient for the diagnosis
[22]. However, for many others, the documentation of
neuroendocrine differentiation is essential to compliment
the characteristic morphologic features [23]. SmCC usu-
ally shows positive staining for chromogranin and synap-
tophysin with strong and diffuse immunoreactivity for
CD56 [22,24]. In our series, CD56 was more sensitive
than chromogranin and synaptophysin as it was positive
in 9 of the 10 cases. In the current study, we excluded
other neuroendocrine tumors as carcinoid, atypical carci-
noid and large cell neuroendocrine carcinomas based on
tumor morphology in order to limit our immunohisto-
chemical assessment to pure small cell carcinomas.
Pancytokeratin (AE1/AE3) and LMWK (Cam5.2) are
reported to be positive in all SmCC [22]. Similar findings
were present in our cases and in addition, CK 7 and 19
expression was also noted in all cases. We also report the
Table 1: The panel of immunohistochemical reagents used
Antibody Clone Manufacturer Pre-treatment Diluti
on
CK 7 OV-TL 12/
30
Dako (Carpinteria, CA) Pepsin for 10 minutes at 37°C 1/4000
CK 20 KS 20.8 Novocastra (Vision Biosystem, Norwell, MA) Pepsin for 10 minutes at 37°C 1/50
Synaptophysin 27G12 Vector (Burlingame, CA) HIER at pH 6.0 1/200
Chromogranin A Polyclonal Dako (Carpinteria, CA) Pepsin for 10 minutes at 37°C 1/200
CD56 123C3 Zymed (Invitrogen, Carlsbad, CA) HIER at pH 6.0 1/200
NSE Polyclonal Dako (Carpinteria, CA) None 1/250
EGFR 31G7 Zymed (Invitrogen, Carlsbad, CA) Pepsin for 10 minutes at 37°C 1/100
LMWK Cam 5.2 B.D. Bioscience (San Jose, CA) Pepsin for 10 minutes at 37°C 1/64
CK 19 6170 Novocastra (Vision Biosystem, Norwell, MA) Pepsin for 10 minutes at 37°C 1/50
Pankeratin AE1/AE3 Dako (Carpinteria, CA) Pepsin for 10 minutes at 37°C 1/300
TTF-1 8G7G3/1 Neomarker (Lab Vision, Fremont, CA) HIER at pH 6.0 1/800
CA 125 Ov185:1 Novocastra (Vision Biosystem, Norwell, MA) HIER at pH 6.0 1:100
CDX2 Amt 28 Vision Biosystem (Norwell, MA) HIER at pH 8.0 1/50
mCEA B80-1 Biomeda (Foster City, CA) None 1/200
HIER = Heat-induced epitope retrieval, in a Biocare decloaking chamberDiagnostic Pathology 2007, 2:35 http://www.diagnosticpathology.org/content/2/1/35
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patterns of staining for cytokeratins 7 and 20 staining with
CK 7+/CK 20- in 4 cases, CK 7-/CK 20+ in 2 cases, and CK
7-/CK 20- in 4 cases. Our series is the first to document the
limitation of CK 20 immunohistochemistry in CRSmCC.
None of the rectal SmCC was positive for CK 20. CK 19
was positive in all 10 cases studied. Since its expression is
also noted in conventional colorectal adenocarcinoma,
CK 19 has a limited value in distinguishing it from
CRSmCC [25]. To the best of our knowledge, there are no
previous reports in the English literature describing the
expression of cytokeratins 7, 19, and 20 in CRSmCC.
Thyroid transcription factor-1 (TTF-1) is a nuclear home-
odomain transcription factor that is expressed in the
developing thyroid, respiratory epithelium, and dien-
cephalon [26]. Several studies have documented that TTF-
1 could not be used in distinguishing pulmonary from
extra-pulmonary SmCC due to the extensive overlap in
these tumors' immunophenotypes. With the exception of
cases with skin tumors, TTF-1 could not be reliably used
to distinguish primary from metastatic SmCC in extra-
pulmonary sites [26-28]. In one study, TTF-1 was reported
to be positive in the vast majority of pulmonary (81%)
and extra-pulmonary (80%) SmCC with the exception of
Merkel cell tumor [28]. Another study reported that TTF-1
was expressed in 82.7% of pulmonary SmCCs, 42.0% of
extra-pulmonary SmCCs (range, 33.3 – 53.3% for the var-
ious sites), and 0% of Merkel cell carcinomas [26]. Inter-
estingly, none of these extra-pulmonary SmCC cases
included in both studies involved the colorectum [26,28].
With relatively limited data, staining for TTF-1 seems to be
uniformly negative in CRSmCC.[29] The results of our
study support this observation highlighting the value of
TTF-1 immunostaining in differentiating SmCC of a
A rectal small cell carcinoma showing positive EGFR immu- nostaining Figure 4
A rectal small cell carcinoma showing positive EGFR immu-
nostaining. (EGFR × 400).
A small cell carcinoma of the ascending colon with immunop- ositivity to CD56 Figure 2
A small cell carcinoma of the ascending colon with immunop-
ositivity to CD56. (CD56 × 400).
A rectal small cell carcinoma showing positive synaptophysin  immunostaining Figure 3
A rectal small cell carcinoma showing positive synaptophysin 
immunostaining. (Synaptophysin × 400).Diagnostic Pathology 2007, 2:35 http://www.diagnosticpathology.org/content/2/1/35
Page 5 of 7
(page number not for citation purposes)
colorectal from that of a pulmonary origin. This is partic-
ularly significant in CRSmCC with lung metastases to
exclude primary lung tumors or in patients with synchro-
nous malignancies. However the presence of CK 20 +/TTF-
1 – subset of CRSmCC highlights the morphological and
immunohistochemical overlap between CRSmCC and
Merkel cell carcinoma. CDX2 and mCEA are rarely
expressed in CRSmCC and hence they may be of value in
differentiating it from poorly differentiated colorectal
adenocarcinoma. To the best of our knowledge, no previ-
ous study has described CDX2 expression in CRSmCC.
The diagnostic value of CDX2 in Merkel cell tumor has
not yet been established.
Seven of our cases showed EGFR expression. Reporting
EGFR immunostaining in conventional primary colorec-
tal adenocarcinoma and its metastasis has extensively
been studied recently [30,31]. The current study is the first
to report EGFR expression in CRSmCC which could have
management and prognostic implications through the
possible use of targeted biological therapy in these
tumors, if similar results are shown in larger series.
Similar to SmCC of the lung, CRSmCC usually presents
with distant metastases [32-34]. Nine of our 10 patients
had metastases at the time of diagnosis. The prognosis of
CRSmCC is worse than that of stage-matched conven-
tional colorectal adenocarcinomas [22]. With the excep-
tion of Merkel cell tumor, the standard management for
SmCC has increasingly become systemic chemotherapy
[35] whether the tumor is pulmonary or extrapulmonary.
In spite of the initial response to chemotherapy, radio-
Table 2: Demographic and clinical summary
Case Age/Sex Site History Present-Ation Metastasis/Site Procedure Associated 
Pathology
Follow up
1 65/M Ileocecal ? Cholecystitis Abdom-inal Pain - Right 
Hemicolectomy 
(pT3 N2)
Tubulovillous 
adenoma with 
invasive 
adenocarcinoma 
adjacent to 
SmCC
DOD
26 9 / M A s c e n d i n g  
colon
Family history of 
colon cancer
Abdominal pain +/Liver Biopsy + Right 
Hemicolectomy 
(pT2 N2)
Adenoma DOD
38 8 / F A s c e n d i n g  
colon
Mass adjacent to 
colon
Pleural Effusion +/Medias-tinal 
lymph nodes and 
liver
Biopsy - DOD
4 42/F Rectum 2 previous 
negative rectal 
biopsies a year 
earlier
Abdominal pain +/Liver Biopsy - AWD
5 43/F Rectum Ulcerative colitis Abdominal Pain 
and weight loss
+/Retro-
peritoneal, 
inguinal lymph 
nodes, liver and 
skin
Biopsy Ulcerative colitis DOD
6 49/F Rectum Rectal villous 
adenoma 2 years 
earlier
Abdominal Pain +/Para-aortic 
lymph nodes and 
liver
Biopsy - DOD
7 59/F Rectum Crohn's disease Abdominal pain +/Para-aortic 
lymph nodes
Biopsy + Low 
anterior resection 
(pT3 N2)
Crohn's disease 
+ 3 tubular 
adenomas away 
from SmCC
DOD
8 66/F Rectum - Stool 
incontinence + 
Rectal pain
+/Groin lymph 
nodes
Biopsy - AWD
9 39/M Rectum - Rectal urgency +/Exten-sion to 
pelvic side walls
Biopsy, loop 
colostomy, then 
abdomino-
perineal resection
SIADH DOD
10 61/F Ano-rectal 
junction
- Rectal bleeding +/Liver Biopsy - AWD
AWD = Alive with disease. DOD = Dead of diseaseDiagnostic Pathology 2007, 2:35 http://www.diagnosticpathology.org/content/2/1/35
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therapy and possibly surgery depending on the extent of
residual disease or response [12,16], patients invariably
relapse and die rapidly of distant metastases.
Conclusion
SmCC is an aggressive tumor of the large bowel with a pre-
dilection for the rectum. This study reports for the first
time the various CK7/CK20 immunostaining patterns
encountered, its predominant negative staining with
CDX2 and the expression of EGFR in more than half of
these tumors. It elaborates on the practical use of immu-
nohistochemistry in the differential diagnosis.
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